Clofazamine showed anti-leukemic potential in CML by modulating transcriptional activity of PPARγ and its subsequent interaction with p65 NF-κB to induce degradation. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.